Erlotinib Resistance is Altered after Gemcitabine Chemotherapy for Recurrent Non-Small-Cell Lung Cancer

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.31, Iss.4, 2011-04, pp. : 279-283

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors

By Danesi Romano Altavilla Giuseppe Giovannetti Elisa Rosell Raffael

Pharmacogenomics, Vol. 10, Iss. 1, 2009-01 ,pp. : 69-80

Future Medicine

Access to resources Recommend Favorite

The Role of Pemetrexed Combined with Gemcitabine for Non-Small-Cell Lung Cancer

Current Drug Targets, Vol. 11, Iss. 1, 2010-01 ,pp. : 61-66

Bentham Science Publishers

Access to resources Recommend Favorite

Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy: A NICE Single Technology Appraisal

By Dickson Rumona

PharmacoEconomics, Vol. 29, Iss. 12, 2011-12 ,pp. : 1051-1062

Adis International

Access to resources Recommend Favorite

Erlotinib in non-small cell lung cancer: a review

By Blackhall Fiona H Rehman Shazza Thatcher Nicholas

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 6, 2005-06 ,pp. : 995-1002

Informa Healthcare

Access to resources Recommend Favorite

Advances in chemotherapy in advanced non-small-cell lung cancer

By Maione Paolo Rossi Antonio Sacco Paola Claudia Bareschino Maria Anna Schettino Clorinda Gridelli Cesare

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 18, 2010-12 ,pp. : 2997-3007

Informa Healthcare

Access to resources Recommend Favorite